All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
#EADV2024: Plaque psoriasis
By Ella Dixon
To update you on the exciting content presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress, we have collated our social media coverage. Catch up with our live social media posts relating to plaque psoriasis below.
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
Diamant Thaçi, @UniLuebeck provides an update on topical treatments for patients with psoriasis.
They highlight the safety and efficacy of topical treatments, including tapinarof and roflumilast, and discuss advancements in drug delivery… pic.twitter.com/57xLiKL1lB
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
Richard Warren, @OfficialUoM examines the role of oral therapies for patients with psoriasis.
They highlight the potential benefits of oral therapies, such as cost and patient preference, and discuss the safety and efficacy of targeted… pic.twitter.com/6AKcjCXv0v
CONGRESS | #EADVCongress | PRESENTATION@Satveer_Mahil, @KingsCollegeLon, shares insights on tailoring disease prevention and treatment approaches by considering individual differences in genetics, molecular, environmental, and lifestyle factors. For patients with new onset of… pic.twitter.com/oAxLOSTNGQ
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
CONGRESS | #EADVCongress | POSTER
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
Matthias Augustin, @UKEHamburg presents results from an analysis of the German Psoriasis Registry PsoBest assessing the change in drug supply and choice of systemic therapies for patients with psoriasis over a 15-year period.
The proportion of… pic.twitter.com/rDGnRx0IKJ
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Ioana Cutcutache shares results from an analysis of the effects of bimekizumab treatment on the PASI sub-components at a molecular and clinical level in patients with plaque psoriasis.
Bimekizumab treatment improved all PASI sub-component… pic.twitter.com/O9GmA1iSn3
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Linfeng Li, Capital Medical University, presents post-hoc subgroup analysis results of a phase III trial (NCT04839016) evaluating the efficacy and safety of vunalizumab in 461 patients with moderate-to-severe #psoriasis, stratified by… pic.twitter.com/RIiH9U0Pn0
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Kilian Eyerich, @UniFreiburg, presents results from part 3 withdrawal phase of the phase IIIb GUIDE study investigating disease-modifying effects of guselkumab in patients with moderate-to-severe plaque #psoriasis (n=273). A total of 26… pic.twitter.com/WBk8Gp7aR3
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Khusru Asadullah, @ChariteBerlin, shares interim findings from part 3 of the phase IIIb GUIDE study assessing maintenance of response after guselkumab withdrawal in super responders (n=273). The median treatment-free period for guselkumab… pic.twitter.com/Z2MI9zAN7f
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Diamant Thaçi, @UniLuebeck highlights results from the interim analysis of the observational VALUE study assessing the real-world effectiveness of risankizumab vs other biologic therapies at 2 years of treatment in adult patients with… pic.twitter.com/BOX9hdirRR
More about...
Your opinion matters
6 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox